Collegium Pharmaceutical's (NASDAQ: COLL) stock soared 7.32% in the after-hours trading session on Thursday, following the company's impressive fourth-quarter earnings report.
The pharmaceutical firm reported quarterly adjusted earnings of $1.75 per share, beating analysts' consensus estimate of $1.54 by a significant margin of 13.64%. The company's revenue also surpassed expectations, coming in at $181.95 million, which is 1.20% higher than the forecasted $179.79 million. Compared to the same period last year, Collegium Pharmaceutical's earnings and sales grew by 10.76% and 21.51%, respectively.
The strong financial performance and better-than-expected results are likely the key factors driving the after-hours surge in Collegium Pharmaceutical's stock price. Investors appear to be reacting positively to the company's ability to deliver solid growth and exceed analysts' estimates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。